S&P 500   3,961.73 (+0.33%)
DOW   32,189.29 (+0.26%)
QQQ   309.87 (+0.04%)
AAPL   159.80 (+0.55%)
MSFT   278.79 (+0.41%)
META   205.43 (+0.56%)
GOOGL   105.05 (-0.52%)
AMZN   98.04 (-0.68%)
TSLA   190.45 (-0.92%)
NVDA   266.02 (-2.17%)
NIO   9.01 (-2.80%)
BABA   86.61 (+0.10%)
AMD   97.63 (-2.64%)
T   18.55 (+0.49%)
F   11.47 (+0.44%)
MU   60.63 (-1.16%)
CGC   1.92 (+0.52%)
GE   90.84 (-0.82%)
DIS   93.93 (-1.98%)
AMC   4.49 (+0.45%)
PFE   40.38 (+0.50%)
PYPL   73.59 (+1.42%)
NFLX   326.60 (+1.94%)
S&P 500   3,961.73 (+0.33%)
DOW   32,189.29 (+0.26%)
QQQ   309.87 (+0.04%)
AAPL   159.80 (+0.55%)
MSFT   278.79 (+0.41%)
META   205.43 (+0.56%)
GOOGL   105.05 (-0.52%)
AMZN   98.04 (-0.68%)
TSLA   190.45 (-0.92%)
NVDA   266.02 (-2.17%)
NIO   9.01 (-2.80%)
BABA   86.61 (+0.10%)
AMD   97.63 (-2.64%)
T   18.55 (+0.49%)
F   11.47 (+0.44%)
MU   60.63 (-1.16%)
CGC   1.92 (+0.52%)
GE   90.84 (-0.82%)
DIS   93.93 (-1.98%)
AMC   4.49 (+0.45%)
PFE   40.38 (+0.50%)
PYPL   73.59 (+1.42%)
NFLX   326.60 (+1.94%)
S&P 500   3,961.73 (+0.33%)
DOW   32,189.29 (+0.26%)
QQQ   309.87 (+0.04%)
AAPL   159.80 (+0.55%)
MSFT   278.79 (+0.41%)
META   205.43 (+0.56%)
GOOGL   105.05 (-0.52%)
AMZN   98.04 (-0.68%)
TSLA   190.45 (-0.92%)
NVDA   266.02 (-2.17%)
NIO   9.01 (-2.80%)
BABA   86.61 (+0.10%)
AMD   97.63 (-2.64%)
T   18.55 (+0.49%)
F   11.47 (+0.44%)
MU   60.63 (-1.16%)
CGC   1.92 (+0.52%)
GE   90.84 (-0.82%)
DIS   93.93 (-1.98%)
AMC   4.49 (+0.45%)
PFE   40.38 (+0.50%)
PYPL   73.59 (+1.42%)
NFLX   326.60 (+1.94%)
S&P 500   3,961.73 (+0.33%)
DOW   32,189.29 (+0.26%)
QQQ   309.87 (+0.04%)
AAPL   159.80 (+0.55%)
MSFT   278.79 (+0.41%)
META   205.43 (+0.56%)
GOOGL   105.05 (-0.52%)
AMZN   98.04 (-0.68%)
TSLA   190.45 (-0.92%)
NVDA   266.02 (-2.17%)
NIO   9.01 (-2.80%)
BABA   86.61 (+0.10%)
AMD   97.63 (-2.64%)
T   18.55 (+0.49%)
F   11.47 (+0.44%)
MU   60.63 (-1.16%)
CGC   1.92 (+0.52%)
GE   90.84 (-0.82%)
DIS   93.93 (-1.98%)
AMC   4.49 (+0.45%)
PFE   40.38 (+0.50%)
PYPL   73.59 (+1.42%)
NFLX   326.60 (+1.94%)
NASDAQ:HALO

Halozyme Therapeutics - HALO Price Target & Analyst Ratings

$34.65
+0.97 (+2.88%)
(As of 03/24/2023 02:40 PM ET)
Add
Compare
Today's Range
$33.42
▼
$34.74
50-Day Range
$32.86
▼
$53.28
52-Week Range
$32.83
▼
$59.46
Volume
910,914 shs
Average Volume
1.54 million shs
Market Capitalization
$4.69 billion
P/E Ratio
23.90
Dividend Yield
N/A
Price Target
$56.13

Halozyme Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$56.13
61.98% Upside
High Prediction$68.00
Average Prediction$56.13
Low Prediction$42.00
TypeCurrent
3/24/22 to 3/24/23		1 Month Ago
2/22/22 to 2/22/23		3 Months Ago
12/24/21 to 12/24/22		1 Year Ago
3/24/21 to 3/24/22
Consensus Rating
Moderate Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$56.13$60.13$59.75$50.50
Predicted Upside61.98% Upside17.23% Upside16.51% Upside36.88% Upside
Get Halozyme Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

HALO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HALO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Halozyme Therapeutics Stock vs. The Competition

TypeHalozyme TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside65.56% Upside1,996.09% Upside25.71% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/16/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform$42.00+16.44%
3/16/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform$42.00+4.87%
3/16/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$65.00 ➝ $55.00+37.33%
3/6/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$65.00 ➝ $64.00+38.02%
2/23/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOverweight$54.00 ➝ $52.00+1.54%
2/22/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform$62.00 ➝ $66.00+32.90%
12/8/2022Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$55.00 ➝ $68.00+17.77%
5/26/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$48.00 ➝ $60.00+30.32%
2/23/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$43.00 ➝ $42.00+28.09%
6/14/2021Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform
1/25/2021BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$56.00 ➝ $65.00+31.31%
12/17/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$50.00+21.62%
12/11/2020Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$29.00 ➝ $41.00+1.33%
6/15/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral$18.00 ➝ $26.00+13.94%
5/4/2020Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Charles Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight$35.00 ➝ $39.00+68.32%
(Data available from 3/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












HALO Price Target - Frequently Asked Questions

What is Halozyme Therapeutics's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Halozyme Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for HALO. The average twelve-month price prediction for Halozyme Therapeutics is $56.13 with a high price target of $68.00 and a low price target of $42.00. Learn more on HALO's analyst rating history.

Do Wall Street analysts like Halozyme Therapeutics more than its competitors?

Analysts like Halozyme Therapeutics more than other Medical companies. The consensus rating for Halozyme Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how HALO compares to other companies.

Is Halozyme Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Halozyme Therapeutics's stock had 2 downgrades by analysts.

Does Halozyme Therapeutics's stock price have much upside?

According to analysts, Halozyme Therapeutics's stock has a predicted upside of 22.28% based on their 12-month price targets.

What analysts cover Halozyme Therapeutics?

Halozyme Therapeutics has been rated by JMP Securities, JPMorgan Chase & Co., Morgan Stanley, SVB Leerink, SVB Securities, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:HALO) was last updated on 3/24/2023 by MarketBeat.com Staff